Rentschler Biopharma Names Martin Kessler as New CEO in U.S.

Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has appointed of Dr. Martin Kessler as CEO of Rentschler Biopharma Inc., the company’s wholly owned U.S. subsidiary, and as senior vice president of transformation of Rentschler Biopharma SE.

Kessler brings more than 15 years of experience in pharmaceutical and biopharmaceutical operations and strategy. At Rentschler Biopharma, he will drive the transformation throughout the company as it grows strategically into new fields and technologies. In his role as head of the U.S. business, he will lead the ongoing expansion at the company’s Greater Boston area site, which includes expanding capabilities, capacity, and talent.

“We are delighted to welcome Martin to Rentschler Biopharma. He is a highly talented executive who already knows our company well, having served in a consulting capacity on critical growth projects for the past few years. I have been impressed with his ability to look at complex problems from a variety of perspectives to find optimal solutions and to effectively implement those plans,” said Frank Mathias, CEO of Rentschler Biopharma SE. “With the further implementation of our strategy 2025, Martin will take the lead role in driving that transformation as we continue to play an important role in vaccine manufacturing to fight the ongoing pandemic and as we move into new areas like cell and gene therapy. As head of Rentschler Biopharma Inc., he will be an important bridge across the Atlantic to ensure seamless operations as the site expands and continue the close and synergistic cooperation true to our motto—many hands, many minds, one team.”

Previously, Kessler held several leadership positions in the industry and in the consulting business before joining Rentschler Biopharma. In his last position, he was associate partner at McKinsey & Company and led the medical device operations practice in Europe. He served leading pharma, biopharma, and med-tech companies in optimizing operations, specifically, supply chain, manufacturing, and quality. He brings additional expertise in strategy and portfolio optimization, as well as clinical development, including in the mRNA space.

As a consultant, he has been working closely with Rentschler Biopharma across a variety of areas, including operations transformation, strategic innovation, and overall strategy for the U.S. site.